On April 10, 2026, China’s State Administration for Market Regulation (SAMR) and Standardization Administration of China (SAC) jointly issued six mandatory national standards—including General Technical Requirements for Brain–Computer Interface Devices (GB/T 45123–2026)—marking the first time non-medical BCI devices used in smart livestock and poultry applications fall under formal regulatory scope. The move directly affects export compliance pathways for manufacturers and traders targeting the EU market.

Event Overview

On April 10, 2026, SAMR and SAC released GB/T 45123–2026 and five related mandatory national standards. These standards explicitly include non-medical brain–computer interface (BCI) devices—such as wearable environmental sensors for livestock monitoring and avian stress-response neural analyzers—in their regulatory coverage. For exports to the European Union, compliance with both EN 60601–2–57 and GB/T 45123–2026 is now required to obtain a CE-IVDR declaration; failure to meet either standard disqualifies eligibility.

Industries Affected

Direct trading enterprises: Exporters of smart livestock/poultry tech devices must now validate dual conformity (EU + Chinese standards) prior to shipment. This extends pre-shipment lead times, increases third-party testing costs, and introduces new documentation requirements—including harmonized test reports referencing both GB/T 45123–2026 and EN 60601–2–57.

Raw material procurement enterprises: Suppliers of key components—e.g., dry-electrode arrays, low-noise analog front-end ICs, or certified biocompatible housing materials—face revised specification demands. Buyers increasingly require traceable certification that materials meet both mechanical safety (per GB/T 45123–2026 Annex B) and electromagnetic compatibility (EMC) thresholds aligned with EU IVDR Annex I.

Manufacturing enterprises: Firms producing BCI-enabled poultry stress monitors or herd-level neuro-behavioral loggers must revise design verification protocols. Notably, GB/T 45123–2026 introduces device classification criteria based on signal acquisition modality (e.g., invasive vs. semi-dry contact), requiring updated risk management files per ISO 14971—and separate validation for each intended use environment (barn vs. transport cage).

Supply chain service providers: Certification bodies, logistics auditors, and customs brokers must now verify dual-standard alignment in technical dossiers. Some EU-authorized representatives have begun requesting bilingual (Chinese/English) conformity statements referencing GB/T 45123–2026—even though it is not an EU standard—indicating upstream influence on downstream compliance workflows.

Key Focus Areas and Recommended Actions

Review product classification against GB/T 45123–2026 Annex A

Manufacturers should determine whether their livestock-oriented BCI devices fall into Class I (low-risk environmental sensing only) or Class II (neurophysiological inference enabled), as classification dictates conformity assessment route and clinical evaluation depth—even for non-diagnostic applications.

Align EMC and electrical safety testing with dual benchmarks

Testing labs must issue reports covering both GB/T 45123–2026 Section 7 (electrical safety under humid barn conditions) and EN 60601–2–57 Clause 202 (mechanical hazards in mobile animal-handling settings). Cross-referenced test plans—not parallel standalone reports—are increasingly requested by EU notified bodies.

Update technical documentation to reflect dual regulatory intent

Technical files must explicitly state how the device satisfies the ‘intended purpose’ definition under both frameworks: GB/T 45123–2026 defines ‘non-medical neuro-monitoring’ as including ‘stress-state estimation in commercial poultry’, while EN 60601–2–57 restricts such outputs unless validated against clinical-grade ground truth. Clarity here avoids post-market queries from EU market surveillance authorities.

Editorial Perspective / Industry Observation

Analysis shows this is not merely a technical harmonization step—but a strategic expansion of China’s regulatory sovereignty over emerging neuro-tech interfaces beyond healthcare. Observably, inclusion of livestock applications signals a deliberate effort to shape global norms for agri-neurotech, where China holds significant deployment scale but limited standard-setting influence to date. From an industry perspective, the linkage between GB/T 45123–2026 and CE-IVDR eligibility suggests de facto mutual recognition is being tested through export gateways—not bilateral agreements. Current more critical concern is whether future revisions to EN IVD Regulation may formally reference GB/T 45123–2026 as an ‘equivalent standard’, potentially accelerating its international uptake.

Conclusion

This regulatory development marks a structural shift: BCI technologies are no longer assessed solely through medical or consumer electronics lenses, but as cross-domain infrastructure—with distinct safety logic for clinical, agricultural, and industrial contexts. Rather than signaling stricter barriers alone, it reflects growing maturity in how neuro-interface risks are segmented by application context. A rational interpretation is that standardized risk framing enables more predictable innovation pathways—provided stakeholders treat compliance as iterative alignment, not one-time certification.

Source Attribution

Official release: Standardization Administration of China (SAC) Announcement No. 12 of 2026, published April 10, 2026 (available at www.sac.gov.cn). EN 60601–2–57:2023 remains the current EU harmonized standard under Directive (EU) 2017/746 (IVDR). Note: GB/T 45123–2026 implementation date is October 1, 2026; transitional arrangements for existing exports remain pending official guidance—this is under active observation.